Expert Interview
Discussing the NASH treatment landscape and the potential of Altimmune's phase 1 study of pemvidutide, a GLP-1/glucagon dual receptor agonist.
Ticker(s): ALT, LLY, NVOInstitution: Cooper University Health Hospital
- Primary care provider who sees 80 patients with NASH
- Assistant professor of medicine who manages patients with metabolic syndrome, DM, HTN, renal and liver disease
- Special interest in preventative care medicine
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
